Lakewood-Amedex Biotherapeutics Inc, a clinical-stage biotech firm focused on developing a new category of powerful, rapid-acting, broad-spectrum antimicrobials known as the Bisphosphocin® class, has announced the addition of Joseph Tucker, Ph.D., to its Board of Directors. Dr. Tucker, who currently serves as Chief Executive Officer of Enveric Biosciences (Nasdaq: ENVB), joins the board following the company’s recent direct listing on Nasdaq. His appointment marks an important move to enhance governance and strategic direction as the company pursues its expansion plans.

With over 20 years of experience in the biotechnology sector, Dr. Tucker brings extensive leadership expertise across both public and private organizations, covering the full spectrum from early discovery to advanced-stage drug development. He leads Enveric Biosciences, a company dedicated to developing innovative neuroplastogenic small-molecule therapies aimed at treating neuropsychiatric and neurological conditions.

Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics, noted that Dr. Tucker offers a strong blend of public company leadership, capital markets knowledge, and drug development expertise. He emphasized that Dr. Tucker’s experience in building and scaling biotech companies, along with his familiarity with public market dynamics, makes him a valuable addition to the board at a crucial stage. Following the Nasdaq listing, the company is prioritizing accelerated growth, and Dr. Tucker’s perspective is expected to support the advancement of its lead candidate, Nu-3, and broader pipeline development.

At Enveric, Dr. Tucker has overseen several strategic financing efforts and pipeline expansion initiatives, including progress toward a first-in-human clinical trial for its lead program, EB-003. Before joining Enveric, he held senior leadership roles—including CEO, Executive Chairman, and Director—at multiple biotechnology firms such as Willow Biosciences and Stem Cell Therapeutics. In these roles, he guided organizations through public offerings, mergers and acquisitions, and the development of clinical programs across diverse therapeutic areas. Throughout his career, he has raised over $100 million in funding, secured substantial non-dilutive capital, and completed numerous partnerships and licensing agreements.

Commenting on his new role, Dr. Tucker expressed enthusiasm about joining Lakewood-Amedex Biotherapeutics during a transformative period. He highlighted that the company’s Nasdaq listing creates a strong foundation for future growth and noted the promising potential of Nu-3 in tackling the global issue of antibiotic resistance. He also underscored the importance of developing new treatments for infected diabetic foot ulcers, an area with significant unmet medical need, and stated his eagerness to collaborate with the team to unlock the platform’s full potential.

You wake up feeling awful—your throat hurts and you’re running a fever. The doctor prescribes antibiotics, and within a few days you start to feel like yourself again. You decide to stop taking the medication early.

It might seem harmless, but it isn’t.

When antibiotics are stopped too soon, the remaining bacteria have a chance to survive, adapt, and develop resistance to the drugs meant to eliminate them. This contributes to a major global health challenge: antimicrobial resistance (AMR).

As AMR grows, infections that were once easy to treat can become dangerous, even deadly. Millions of people around the world already die each year from drug-resistant infections. The encouraging news is that we can all help slow the spread of resistance by taking a few simple steps:

From Production to the Pharmacy Shelf
We are committed to combating AMR by ensuring responsible manufacturing practices, monitoring our supply chain, and supporting education for both healthcare professionals and patients.

Over the past two years, Teva has received two BSI (British Standards Institution) certifications for responsible antibiotic production. We keep a close watch on our facilities to prevent antibiotic residues from entering the environment, and we work with our suppliers to uphold the same standards. Antibiotics in wastewater or surrounding ecosystems can encourage bacteria to evolve and become more resistant.

Reaching Patients in Meaningful Ways
To promote better antibiotic use and prescribing habits, we collaborate with Clarivate on targeted pilot initiatives tailored to local healthcare systems and community needs.

In Germany, one pilot featured brief messages on pharmacy display screens for patients collecting antibiotic prescriptions. More than 389,000 digital reminders were also sent to pharmacists, helping them guide patients on safe antibiotic use. The impact was clear—77% of pharmacists reported that these materials supported more productive conversations with their patients.

In Kenya, the program integrates reminders directly into Electronic Health Record (EHR) systems so physicians receive real-time prompts about appropriate prescribing. Patients also get SMS reminders—delivered in their local language—to finish their medication. Insights from this project revealed common misconceptions, such as the belief that antibiotics can treat colds, as well as challenges like limited access to diagnostic tools, both of which can increase the likelihood of inappropriate use and rising AMR.

There is still progress to be made, and every one of us can contribute. By working together, we can safeguard the effectiveness of antibiotics and ensure they remain powerful tools for future generations.